Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$3.28 – $11.10
96% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.0K | $30.8M | $765.0K | $80.1M | $20.2M | $28.6M | $67.0M | $65.4M |
| Cost of revenue | $1.9M | $177.0K | $202.0K | $161.0K | $248.0K | $341.0K | $300.0K | $50.9M |
| Gross profit | −$1.8M | $30.7M | $563.0K | $79.9M | $19.9M | $28.2M | $66.7M | $14.5M |
| Gross margin | -2587.0% | 99.4% | 73.6% | 99.8% | 98.8% | 98.8% | 99.6% | 22.2% |
| R&D | $47.7M | $66.2M | $59.1M | $35.2M | $35.8M | $46.7M | $47.2M | $52.8M |
| Operating income | −$69.5M | −$57.8M | −$82.9M | $31.8M | −$27.3M | −$26.6M | $3.3M | −$58.9M |
| EBITDA | −$68.1M | −$49.0M | −$73.0M | $34.9M | −$25.8M | −$22.2M | $8.3M | −$8.0M |
| Net income | −$79.5M | −$65.1M | −$101.2M | $67.3M | −$23.7M | −$28.9M | $1.5M | −$85.9M |
| Net margin | -115247.8% | -211.2% | -13231.5% | 84.0% | -117.5% | -101.2% | 2.2% | -131.4% |
| EPS (diluted) | -2.55 | -1.76 | -2.60 | 1.23 | -0.48 | -0.58 | 0.03 | -1.73 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $85M | $0.12 | $0.07–$0.18 | 1 |
| 2027 | $99M | $0.15 | $0.09–$0.22 | 1 |
| 2028 | $118M | $0.52 | $0.33–$0.78 | 1 |
| 2029 | $294M | $2.73 | $1.75–$4.10 | 1 |
Forward consensus · source: Financial Modeling Prep
GENFIT ORD
No one on the platform currently holds GNFTF.
No tracked institution reports a position in GNFTF as of their last filing.
No one on the platform has traded GNFTF yet.
| $99M |
| — |
| MLLCFMolecular Partners AG | $3.60 | +0.00% | $135M | — |
| NDTPNDT Pharmaceuticals Inc. | $0.47 | +0.00% | $76M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 13.1× sales vs its 5.1× historical median P/S.
Fair value ≈ $4.19 · price $10.75 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.